(ii) We determined the onset of ROS-scavenging adaptive mechanisms, such as increased GSTP1 following Au treatment, and the high significant positive correlation between TrxR1 and 7 GSH system components in the TCGA datasets of patients newly diagnosed with GBM, in addition to (iii) the ability of pro-oxidant Trx/GSH inhibitors to bypass redox compensatory mechanisms in GSCs and exhibit strong cytotoxic synergy regardless of wtp53 expression levels and mutant-p53 in GSCs. This evidence concerns the gene TXN and glioblastoma.